ProLynx Inc is a clinical-stage biopharmaceutical company specializing in the development of novel long-acting therapeutics. We are leveraging our drug delivery platform technology to enhance the delivery, half-life, efficacy, and safety of drugs. ProLynx’s technology enables predictable and controllable half-life extension of drugs – including peptides, proteins and small molecules – using nano, macromolecular and fix supports (SC, IV & IT injectables, implants, and others). This technology improves the pharmacokinetics, pharmacodynamics, and reduced dosing frequency compared to conventional delivery methods.
Looking for a particular Prolynx employee's phone or email?
The Prolynx annual revenue was $1 million in 2026.
Richard King is the CEO of Prolynx.
3 people are employed at Prolynx.
Prolynx is based in San Francisco, California.
The NAICS codes for Prolynx are [32541, 325, 32, 3254].
The SIC codes for Prolynx are [28, 283].